Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1999
Business Overview: Regeneron is a biotechnology company focused on discovering and developing novel therapeutics, primarily protein-based, for human medical conditions. Key programs include AXOKINE (obesity/diabetes), BDNF and NT-3 (neurological conditions), angiogenesis, and cytokine traps. The company relies heavily on collaborative agreements with major partners including Procter & Gamble, Amgen, Merck, and Sumitomo Pharmaceuticals.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 1999 | 9 Months Ended Sep 30, 1999 | 9 Months Ended Sep 30, 1998 |
|---|---|---|---|
| Total Revenues | $12,536 | $26,624 | $36,011 |
| Net Loss | ($4,925) | ($21,688) | ($3,084) |
| Net Loss Per Share (Basic/Diluted) | ($0.16) | ($0.69) | ($0.10) |
| Cash and Cash Equivalents | $23,525 | $23,525 | $22,594 |
| Marketable Securities | $40,457 | $40,457 | $66,022 |
| Total Current Assets | $74,281 | $74,281 | $92,901 |
| Total Current Liabilities | $8,873 | $8,873 | $9,402 |
| Accumulated Deficit | ($198,921) | ($198,921) | ($177,233) |
Liquidity: As of September 30, 1999, the company held approximately $87.4 million in cash, cash equivalents, and marketable securities. The company has no established banking arrangements for short-term financing or lines of credit.
Material Changes vs. Prior Period
- Revenue Decline (9 Months): Total revenue decreased 26% to $26.6 million from $36.0 million in the prior year. This was primarily due to the absence of $9.5 million in non-recurring research progress payments received in 1998 from Sumitomo Pharmaceuticals and Procter & Gamble.
- Contract R&D Revenue Increase: Despite the overall decline, contract research and development revenue increased to $15.3 million (9 months 1999) from $14.8 million (9 months 1998), driven by increased quarterly research support from Procter & Gamble ($7.0 million/quarter starting Q3 1999 vs. $1.1 million previously).
- Expense Growth: Total operating expenses increased to $48.3 million (9 months 1999) from $39.1 million (9 months 1998). Research and development expenses rose to $35.0 million, reflecting higher staffing and increased clinical trial activity.
- Net Loss Expansion: Net loss widened significantly to $21.7 million for the nine months ended September 30, 1999, compared to $3.1 million in the same period of 1998, due to increased R&D spending and lower investment income.
- AXOKINE Rights Return: Procter & Gamble returned product rights for AXOKINE to Regeneron in Q3 1999 following interim Phase I safety study results. P&G will continue to provide research support under the broader agreement but will not make further AXOKINE-specific payments.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur substantial funding requirements for R&D, clinical testing, and capital contributions to the Amgen-Regeneron partnership. The company believes existing capital resources will meet operating needs for at least several years.
- Future Funding: The company estimates it could receive up to $90 million or more from Procter & Gamble through mid-2002 in the form of research funding and equity purchases.
- Key Risks:
- Clinical Trial Failure: Significant risk that product candidates (AXOKINE, BDNF, NT-3) may fail to demonstrate safety or efficacy. AXOKINE trials showed adverse events including herpes cold sores and a recurrence of Bell's palsy in one patient.
- Collaboration Termination: Cancellation of material agreements (e.g., with P&G or Amgen) could materially adversely affect operations.
- Antibody Response: Administration of recombinant proteins may cause immune responses (neutralizing antibodies), potentially rendering treatments ineffective.
- Year 2000 Compliance: The company is not currently Year 2000 compliant. While projected remediation costs are under $1.0 million, failure of third-party vendors or utilities to be compliant could disrupt operations.
- Unusual Items: The filing notes a loss in the Amgen-Regeneron Partners of $2.5 million for the nine months ended September 30, 1999, attributed to increased clinical trial activity.
Investor Verification Checklist
- AXOKINE Clinical Data: Verify the final results of the Phase I safety study and the specific criteria for the planned Phase II dose-ranging trial in HSV-negative patients.
- Procter & Gamble Agreement Terms: Confirm the specific timeline and conditions for the increased quarterly research support ($6.3 million+ per quarter) and the potential for future equity purchases.
- Amgen-Regeneron Partnership Status: Review the progress of BDNF and NT-3 clinical trials, specifically the subcutaneous BDNF study for ALS and NT-3 for constipation, to assess the sustainability of the partnership's losses.
- Year 2000 Remediation: Assess the status of the Year 2000 contingency plan and the readiness of critical vendors and utility providers.
- Cash Burn Rate: Monitor the rate of cash consumption given the lack of commercial product revenue and the reliance on collaboration funding and investment income.